Corrigendum to "Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study" [Clin Therapeut 42 (12) (2020) 2254-2265]
Clin Ther
.
2021 Apr;43(4):791.
doi: 10.1016/j.clinthera.2021.01.019.
Epub 2021 Apr 1.
Authors
Timothy R Smith
1
,
Marina Janelidze
2
,
George Chakhava
3
,
Roger Cady
4
,
Joe Hirman
5
,
Brent Allan
6
,
Susan Pederson
4
,
Jeff Smith
6
,
Barbara Schaeffler
4
Affiliations
1
StudyMetrix Research, St. Peters, MO, USA. Electronic address: tsmith@studymetrix.com.
2
Department of Neurology, Tbilisi State Medical University, Tbilisi, Georgia.
3
Multiprofile Clinic Consilium Medulla, Georgian Association of Medical Specialties, Tbilisi, Georgia.
4
Lundbeck Seattle BioPharmaceuticals Inc, Bothell, WA, USA.
5
Pacific Northwest Statistical Consulting Inc, Woodinville, WA, USA.
6
Alder BioPharmaceuticals Inc (now Known as Lundbeck Seattle BioPharmaceuticals Inc), Bothell, WA, USA.
PMID:
33814199
DOI:
10.1016/j.clinthera.2021.01.019
No abstract available
Publication types
Published Erratum